Search

Resume La greffe allogenique de cellules souches hematopoietiques (CSH) est une therapeutique usuelle pour de nombreuses maladies hematologiques. Au cours des dernieres decennies, des progres importants ont ete realises dans les domaines de la prise en charge des patients. La selection des donneurs, les conditionnements de greffe et les soins de support des patients ont contribue a l’amelioration de la survie des patients. La plupart des procedures en rapport avec la greffe allogenique de CSH ont ete standardisees par des recommandations nationales ou internationales amenant a des certifications telles que Joint Accreditation Committee ISCT-Europe & EBMT (JACIE). Mais tous ces standards et ces recommandations ne definissent pas de facon precise les moyens minimums humains et materiels necessaires a la realisation de telles procedures. En plus, les unites dans lesquelles sont places ces patients sont soumises a des regles architecturales et procedurales non uniformisees. Lors de cet atelier, nous avons tente de definir une trame minimale concernant le personnel, l’infrastructure architecturale et des pratiques d’hygiene generales pour les patients, le personnel et les visiteurs.

Since 2010 there has been an exponential increase of the number of transplants performed from related donors. The development of haploidentical transplants increases the resort to related-donation, which presents two main advantages: a less important financial cost and a faster availability of the graft. Standards for mandatory accreditation exist, but the adherence to these recommendations is not optimal: currently, different practices regarding the organizational modalities of care, recruitment criteria, qualification and follow-up of related donors have been observed among French transplant centers. The Francophone Society of Marrow Transplant and Cellular Therapy (SFGM-TC) has developed guidelines for the consent and the non-eligibility criteria for hematopoietic stem cell donors. A multidisciplinary group has devised a booklet as a medium to inform donors about hematopoietic cell donation and transplantation in a clear and accessible language. This paper provides recommendations on post-donation follow-up, taking into account both medical standards and organizational constraints of French centers. Some tools are proposed.

The development of haplo-identical transplants brings to an increased resort to related donation: from 2005 till 2015, this resort increased by 291 %. Beyond the less important financial costs, the related donation also presents the advantage of a faster availability of the donor, avoiding risk of relapse before the procedure.In spite of the existing recommendations, we notice a diversity of the practices among French centers as for the organizational modalities of care, for recruitment criteria, qualification and follow-up of related donors.French Society of Marrow Transplant and Cellular Therapy proposed recommendations concerning the consent and non-qualification criteria of related donors. A multidisciplinary group to facilitate the information about Hematopoietic stem cells donation and transplantation conceived a notebook.In the present article, we propose recommendations for post-donation follow-up, taking into account at the same time medical imperatives and organizational constraints of transplantation teams. Some tools are also presented., Le développement des greffes haplo-identiques amène à un recours de plus en plus important aux donneurs apparentés : de 2005 à 2015, ce recours s’est accru de 291%. Au-delà des coûts financiers moins importants, le don intrafamilial présente également l’avantage d’une disponibilité plus rapide du donneur, évitant ainsi des risques de rechute avant la procédure.En dépit des recommandations existantes, on constate une diversité des pratiques dans les différents centres français quant aux modalités organisationnelles de prise en charge, aux critères de recrutement, qualification et suivi des donneurs apparentés. La Société Française de Greffe de Moelle et Thérapie Cellulaire a fait des propositions concernant le consentement et les critères de non-qualification des donneurs apparentés de cellules souches hématopoïétiques. Un livret a été conçu par un groupe multidisciplinaire afin de faciliter l’information sur le don et sur l’allogreffe. Dans le présent article, prenant en compte à la fois les impératifs médicaux de surveillance et les contraintes organisationnelles des centres greffeurs, nous proposons des recommandations pour le suivi des donneurs apparentés. Quelques outils (documents d’information, questionnaires) sont présentés.

Providing information to living donors is first and foremost a legal obligation as well as an ethical one, not to mention necessary to health care provision. It's been shown that quality of information concerning the procedure's practical aspects, scheduling of clinical tests and examinations, withdrawing stem cells for the donation, post-donation symptoms, and support provided by healthcare teams, directly impacts the donor's quality of experience. Taking this into consideration our group decided it was essential to create an informational support for donors in the form of a booklet to be provided in different hematopoietic stem cell transplant centers across France. In September 2016 in Lille, France, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th allergenic hematopoietic stem cell transplantation clinical practices harmonization workshops. As part of these workshops, our group worked collectively to develop a basis of indispensable information to be included in the booklet and presented using clear and accessible language.

Within the context of the SFGM-TC's 6th workshop series on the harmonization of clinical practices, our workshop proposes a standardization of the informed consent process for hematopoietic stem cell donors and recipients leading up to an autologous or allogenic transplantation. All informed consent was for bone marrow or peripheral stem cell donors, and mononuclear/lymphocyte donors according to usual procedures. The informed consent for autologous and allogenic related or unrelated adults and pediatric transplantation patients have been included. A first step has been conducted for collecting in advance the informed consent forms used routinely in all francophone transplantation centers. In a second step, a comprehensive version has been re-written by a multidisciplinary team. For the purposes of understanding the risks and advantages, language has been carefully considered and streamlined. In the third step, texts were sent to stem cell transplantation experts, experts at the French biomedical agency (agence de la biomédecine [ABM]), law specialists, members of the ethical committee of the French society of hematology and several transplant recipients to be edited and proofread.